Alluvi, formerly BI 4744, offers a promising breakthrough in obesity treatment. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates impressive effectiveness https://minibookmarks.com/story22092101/alluvi-a-detailed-dive-into-the-medication-s-prospects